Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $22.00 Price Target at Citigroup

Key Points

• Citigroup cut its price target on Ultragenyx from $32 to $22 but maintained a Buy rating; the new target implies 41.48% upside from the prior close.
• Analyst views are mixed: the stock has an average Hold rating and a consensus price target of $29.79.
• Third-quarter results missed estimates, with a loss of $1.16 per share and revenue of $173 million. The company reaffirmed its 2027 profitability goal and announced agreements to sell two Priority Review Vouchers for a combined $413 million.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its target price decreased by Citigroup from $32.00 to $22.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. Citigroup's price objective indicates a potential upside of 41.48% from the company's previous close.

A number of other equities research analysts also recently issued reports on the company. Guggenheim lowered their price target on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a "buy" rating for the company in a research report on Tuesday, August 4th. Wells Fargo & Company upped their target price on Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Evercore downgraded shares of Ultragenyx Pharmaceutical from an "outperform" rating to an "in-line" rating and set a $16.00 price target on the stock. in a research note on Thursday, September 3rd. Bank of America lowered shares of Ultragenyx Pharmaceutical from a "buy" rating to a "neutral" rating in a research note on Thursday, September 3rd. Finally, Cantor Fitzgerald increased their price objective on shares of Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the stock an "overweight" rating in a research note on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $29.79.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE traded down $1.61 during trading hours on Thursday, reaching $15.55. 5,383,217 shares of the company traded hands, compared to its average volume of 2,885,698. Ultragenyx Pharmaceutical has a 1-year low of $12.73 and a 1-year high of $39.89. The firm's 50-day moving average is $16.45 and its 200-day moving average is $22.78. The stock has a market cap of $1.53 billion, a P/E ratio of -3.00 and a beta of 0.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The company had revenue of $173.00 million for the quarter, compared to analysts' expectations of $182.49 million. The company's revenue was up 8.2% compared to the same quarter last year. During the same period last year, the firm earned ($1.81) earnings per share. As a group, research analysts predict that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $15.27, for a total value of $107,897.82. Following the completion of the transaction, the chief financial officer owned 89,229 shares in the company, valued at approximately $1,362,526.83. This represents a 7.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 8,510 shares of company stock worth $127,561. Insiders own 5.20% of the company's stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Versant Capital Management Inc raised its holdings in Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 1,001 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at approximately $48,000. Harbor Investment Advisory LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at approximately $52,000. Parallel Advisors LLC boosted its stake in Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 1,440 shares during the period. Finally, Leonteq Securities AG boosted its stake in Ultragenyx Pharmaceutical by 288.5% in the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 1,333 shares during the period. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The company said two Priority Review Vouchers are under agreement to be sold for a combined $413 million, and it reaffirmed its expectation of profitability in 2027. It also reported FDA approval of GENGLYCOS and FAYUVI. Company results and guidance
• Positive Sentiment: Despite trimming its price target, Barclays maintained an “overweight” rating at $32. Canaccord also retained a “buy” rating after lowering its target to $34, signaling some analysts still see substantial upside. Barclays rating
• Neutral Sentiment: Ultragenyx’s third-quarter revenue rose 8.2% year over year to $173 million, but remained below analyst expectations. Its loss narrowed from the year-ago quarter. Quarterly results
• Negative Sentiment: Results missed estimates: the loss was $1.16 per share versus consensus of $1.10, and revenue was $173 million versus expectations of about $182.5 million. The shortfall may be weighing on sentiment. Q3 earnings report
• Negative Sentiment: The 2027 profitability target relies on major cost reductions, including at least a 50% cut in R&D spending versus 2025. That may support near-term finances but raises concerns about pipeline investment and future growth; an analyst commentary also highlighted limited contributions from newer launches and pipeline setbacks. Analyst commentary on the commercial pivot

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx's commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.